Point72 Middle East FZE’s Regenxbio RGNX Stock Holding History

Point72 Middle East FZE’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-30,671	Closed	-$551K	–	1057
2023 Q4	$551K	Buy	+30,671	New	+$540K	0.02%	797
2023 Q3	–	Sell	-15,014	Closed	-$300K	–	1804
2023 Q2	$300K	Buy	+15,014	New	+$289K	0.01%	932
2023 Q1	–	Sell	-2,288	Closed	-$51.9K	–	2104
2022 Q4	$51.9K	Buy	+2,288	New	+$51.7K	﹤0.01%	1446

Other funds holding RGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Point72 Middle East FZE's RGNX Position: Q1 2024 in Review

Point72 Middle East FZE sold out of Regenxbio (RGNX) in Q1 2024, closing a stake of 30,671 shares — an estimated $551K sold.

Point72 Middle East FZE first reported a position in RGNX in Q4 2022 and held it in 3 quarters. The position peaked at $551K in Q4 2023. 188 funds tracked by Wall St. Rank hold RGNX as of Q1 2024.

Point72 Middle East FZE reported no remaining Regenxbio position as of Q1 2024 after selling out during the quarter.
Point72 Middle East FZE sold 30,671 Regenxbio shares in Q1 2024, an estimated $551K.
Point72 Middle East FZE first reported a position in Regenxbio in Q4 2022 and held it in 3 quarters.
Point72 Middle East FZE's Regenxbio position peaked at $551K in Q4 2023.
188 funds tracked by Wall St. Rank held Regenxbio as of Q1 2024.

Based on Point72 Middle East FZE's 13F filing for Q1 2024.